Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
124.18
-0.17 (-0.14%)
Official Closing Price
Updated: 8:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
5 Healthcare Stocks to Buy for 2024
↗
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Healthcare And Biotech Stocks Review: Q1 2024 Performance
↗
April 01, 2024
We just had one of the best first quarters in recent market history since Q1 in 2019 when the market was up 13%. But changes in sector performance may be coming. The S&P 500 was up 10% showing a slight...
Via
Talk Markets
Topics
Stocks
2 Top Biotech Buyout Candidates
↗
March 31, 2024
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be...
Via
Talk Markets
3 Top ETFs I Plan to Buy in April
↗
March 31, 2024
These ETFs are easy, low-cost ways to invest in certain themes.
Via
The Motley Fool
Topics
ETFs
AskSlim Market Week - Friday, March 28
↗
March 28, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
3 Biotech Stocks to Buy on the Dip: March 2024
↗
March 27, 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Via
InvestorPlace
Tuesday Talk: Big-Tech Under Attack
↗
March 26, 2024
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
Via
Talk Markets
Biotechnology And Healthcare, A Bit Of A Lull
↗
March 25, 2024
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors.
Via
Talk Markets
3 Biotech ETFs Overdue for a Bounce
↗
March 19, 2024
The biotech ETFs have been under serious pressure in recent years. Newfound momentum and looming lower rates could spark a comeback.
Via
InvestorPlace
Topics
ETFs
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
↗
March 11, 2024
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.
Via
Talk Markets
Are We Listening To The Market's Message?
↗
March 08, 2024
This week's video features chart/fact-based Q & A covering major stock market indexes, ETFs, the economy, homebuilders, regional banks, semiconductors, value stocks, energy stocks, biotech, and more.
Via
Talk Markets
Topics
ETFs
Economy
“Advance Is Advancing” Stock Market (And Sentiment Results)…
↗
February 29, 2024
Commentary on the stock market, economy, inflation, biotech, and auto sales, as well as a deep dive into Advance Auto Parts.
Via
Talk Markets
Topics
Economy
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
↗
February 28, 2024
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined...
Via
Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
↗
February 28, 2024
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Via
Investor's Business Daily
Opportunities For Investors Beyond AI And Nvidia – Biotech Breaks Out, New GDP Data Shows Inflation Pressure
↗
February 28, 2024
To gain an edge, this is what you need to know today.
Via
Benzinga
Topics
Artificial Intelligence
Economy
ETF Theme: Range-Bound
↗
February 25, 2024
Here is the fund for the emerging markets, which is not only range-bound but seems to be following a regular time pattern.
Via
Talk Markets
Topics
ETFs
Healthcare Stocks Are Looking Better But What About Biotech?
↗
February 20, 2024
Large cap biopharmacuiticals remain a core holding for growth and value despite political cross-currents on drug pricing.
Via
Talk Markets
Favoring IWM, XBI, And KRE
↗
February 18, 2024
It's time to employ ratios. Just like I utilize sector ratios such as XLF to XLU, XLY to XLP, or SPY to TLT, this is the time to look at IWM in comparison to the SPY.
Via
Talk Markets
Sunday ETF Review, Feb. 4, 2024
↗
February 04, 2024
Examining my
Via
Talk Markets
Topics
ETFs
Biotech And Medtech Portfolio Notes On A Fed Day
↗
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
↗
January 26, 2024
There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
↗
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Biotech Playbook: Small Caps Show Momentum Peaking During
↗
January 15, 2024
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market.
Via
Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
↗
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
↗
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2023 in Review: Key Stock Trends and Sector Shifts Unveiled
↗
January 05, 2024
Investors would be smart to pay attention to these stock trends, many of which are taking hold as the New Year begins.
Via
InvestorPlace
Satori Fund's Dan Niles Names Amazon, Meta Top Stocks To Own In 2024
↗
January 03, 2024
Satori Fund founder and portfolio manager Dan Niles is out with his top stock picks for 2024 and two Magnificent 7 names are at the top of the list.
Via
Benzinga
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
↗
January 03, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Via
The Motley Fool
3 Thematic Growth ETFs to Load Up on Right Now
↗
December 30, 2023
These three thematic ETFs could be potent growth vehicles in years to come.
Via
The Motley Fool
Topics
ETFs
Small Caps Are On A Tear Including Speculative Biotechs
↗
December 26, 2023
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.